Michal Sarfaty

9PUBLICATIONS
37CO-AUTHORS
Molecular targetsPredictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Time-series analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 05, 2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial.

Gopa Iyer, Catherine M Tangen, Michal Sarfaty

|Oct 16, 2024
Low Serum Alanine Aminotransferase Blood Activity Is Associated with Shortened Survival of Renal Cell Cancer Patients and Survivors: Retrospective Analysis of 1830 Patients.

Menachem Laufer, Michal Sarfaty, Eyal Jacobi

|Sep 08, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.

Brendan J Guercio, Michal Sarfaty, Min Yuen Teo

|Mar 17, 2023
Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.

Michal Sarfaty, Mahdi Golkaram, Samuel A Funt

|Jul 09, 2022
RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era.

Shira Sagie, Michal Sarfaty, Meital Levartovsky

|Feb 25, 2022
Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma.

Shira Sagie, Moran Gadot, Meital Levartovsky

Pageof 2

Frequent Collaborators

4 joint publications

Ashley Regazzi

4 joint publications

Jonathan E Rosenberg

3 joint publications

Hikmat Al-Ahmadie

3 joint publications

Gopa Iyer